DPP4 and myocardial infarction: The CV outcomes trials of DPP4 inhibitors have shown no beneficial effects of DPP4 inhibitors on CV outcomes; however, no increase in the risk of major adverse CV events, such as the combined MACE outcome (CV death, nonfatal myocardial infarction and non-fatal stroke), versus standard care was noted.